NCT00754455View on ClinicalTrials.gov

Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

317

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza VLP Vaccine (recombinant)

Single injection Day 0; 0.5mL

BIOLOGICAL

Placebo

Placebo as a single injection of 0.5 mL.

Trial Locations (4)

33024

University Clinical Research, Pembroke Pines

64114

The Center for Pharmacuetical Research, Kansas City

78705

Benchmark Research, Austin

02886

Omega Medical Research, Warwick

Sponsors

Lead Sponsor

Novavax
All Listed Sponsors
lead

Novavax

INDUSTRY